Principles and practice of intravitreal application of drugs

Phoebe Lin, Shivali Menda, Eugene de Juan

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Over the last 10 years, the success of anti-vascular endothelial growth factor (VEGF) antibodies for the treatment of neovascular age-related macular degeneration (AMD) has made the use of intravitreal injections for the treatment of posterior segment disease commonplace. The application of drugs into vitreous, as either a direct intraocular injection or in the form of sustained-release devices, is currently the focus of many clinical studies to treat a number of retinal and choroidal diseases. The advantages of this approach are that local treatment bypasses the systemic side effects of a drug and enables more direct control over the dose and duration of drug delivery to the target site. Furthermore, as we gain an increased understanding of the pathophysiological processes in diseases such as vitreomacular traction syndrome and diabetic retinopathy, new pharmacologic treatments have arisen that have the potential to obviate the need for surgical intervention or at least facilitate surgery.

Original languageEnglish (US)
Title of host publicationVitreous: In Health and Disease
PublisherSpringer New York
Pages509-521
Number of pages13
ISBN (Print)9781493910861, 9781493910854
DOIs
StatePublished - Jan 1 2014

Fingerprint

Pharmaceutical Preparations
Choroid Diseases
Intraocular Injections
Retinal Diseases
Intravitreal Injections
Macular Degeneration
Traction
Diabetic Retinopathy
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Vascular Endothelial Growth Factor A
Equipment and Supplies
Antibodies
Clinical Studies

Keywords

  • Age-related macular degeneration
  • Cystoid macular edema
  • Drug delivery
  • Drug release implants
  • Intravitreal injections
  • Microparticles
  • Nanoparticles
  • Sustained drug release
  • Uveitis
  • Vitreous

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lin, P., Menda, S., & de Juan, E. (2014). Principles and practice of intravitreal application of drugs. In Vitreous: In Health and Disease (pp. 509-521). Springer New York. https://doi.org/10.1007/978-1-4939-1086-1_29

Principles and practice of intravitreal application of drugs. / Lin, Phoebe; Menda, Shivali; de Juan, Eugene.

Vitreous: In Health and Disease. Springer New York, 2014. p. 509-521.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lin, P, Menda, S & de Juan, E 2014, Principles and practice of intravitreal application of drugs. in Vitreous: In Health and Disease. Springer New York, pp. 509-521. https://doi.org/10.1007/978-1-4939-1086-1_29
Lin P, Menda S, de Juan E. Principles and practice of intravitreal application of drugs. In Vitreous: In Health and Disease. Springer New York. 2014. p. 509-521 https://doi.org/10.1007/978-1-4939-1086-1_29
Lin, Phoebe ; Menda, Shivali ; de Juan, Eugene. / Principles and practice of intravitreal application of drugs. Vitreous: In Health and Disease. Springer New York, 2014. pp. 509-521
@inbook{3d5e21f6524c453786569caeaae1f971,
title = "Principles and practice of intravitreal application of drugs",
abstract = "Over the last 10 years, the success of anti-vascular endothelial growth factor (VEGF) antibodies for the treatment of neovascular age-related macular degeneration (AMD) has made the use of intravitreal injections for the treatment of posterior segment disease commonplace. The application of drugs into vitreous, as either a direct intraocular injection or in the form of sustained-release devices, is currently the focus of many clinical studies to treat a number of retinal and choroidal diseases. The advantages of this approach are that local treatment bypasses the systemic side effects of a drug and enables more direct control over the dose and duration of drug delivery to the target site. Furthermore, as we gain an increased understanding of the pathophysiological processes in diseases such as vitreomacular traction syndrome and diabetic retinopathy, new pharmacologic treatments have arisen that have the potential to obviate the need for surgical intervention or at least facilitate surgery.",
keywords = "Age-related macular degeneration, Cystoid macular edema, Drug delivery, Drug release implants, Intravitreal injections, Microparticles, Nanoparticles, Sustained drug release, Uveitis, Vitreous",
author = "Phoebe Lin and Shivali Menda and {de Juan}, Eugene",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1086-1_29",
language = "English (US)",
isbn = "9781493910861",
pages = "509--521",
booktitle = "Vitreous: In Health and Disease",
publisher = "Springer New York",

}

TY - CHAP

T1 - Principles and practice of intravitreal application of drugs

AU - Lin, Phoebe

AU - Menda, Shivali

AU - de Juan, Eugene

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Over the last 10 years, the success of anti-vascular endothelial growth factor (VEGF) antibodies for the treatment of neovascular age-related macular degeneration (AMD) has made the use of intravitreal injections for the treatment of posterior segment disease commonplace. The application of drugs into vitreous, as either a direct intraocular injection or in the form of sustained-release devices, is currently the focus of many clinical studies to treat a number of retinal and choroidal diseases. The advantages of this approach are that local treatment bypasses the systemic side effects of a drug and enables more direct control over the dose and duration of drug delivery to the target site. Furthermore, as we gain an increased understanding of the pathophysiological processes in diseases such as vitreomacular traction syndrome and diabetic retinopathy, new pharmacologic treatments have arisen that have the potential to obviate the need for surgical intervention or at least facilitate surgery.

AB - Over the last 10 years, the success of anti-vascular endothelial growth factor (VEGF) antibodies for the treatment of neovascular age-related macular degeneration (AMD) has made the use of intravitreal injections for the treatment of posterior segment disease commonplace. The application of drugs into vitreous, as either a direct intraocular injection or in the form of sustained-release devices, is currently the focus of many clinical studies to treat a number of retinal and choroidal diseases. The advantages of this approach are that local treatment bypasses the systemic side effects of a drug and enables more direct control over the dose and duration of drug delivery to the target site. Furthermore, as we gain an increased understanding of the pathophysiological processes in diseases such as vitreomacular traction syndrome and diabetic retinopathy, new pharmacologic treatments have arisen that have the potential to obviate the need for surgical intervention or at least facilitate surgery.

KW - Age-related macular degeneration

KW - Cystoid macular edema

KW - Drug delivery

KW - Drug release implants

KW - Intravitreal injections

KW - Microparticles

KW - Nanoparticles

KW - Sustained drug release

KW - Uveitis

KW - Vitreous

UR - http://www.scopus.com/inward/record.url?scp=84942046345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942046345&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1086-1_29

DO - 10.1007/978-1-4939-1086-1_29

M3 - Chapter

SN - 9781493910861

SN - 9781493910854

SP - 509

EP - 521

BT - Vitreous: In Health and Disease

PB - Springer New York

ER -